Introduction
Gene transfer vectors based on retroviruses including gamma retroviruses and lentiviruses provide effective means for the delivery, integration and expression of exogenous genes in mammalian cells. In particular, lentiviral vectors represent attractive gene delivery vehicles because of their ability to integrate genetic material into the genomes of non-dividing cells. 1, 2 Indeed, many potential target cells for gene transfer include neurons, myocytes, hepatocytes and hematopoietic stem cells, and many efforts have been carried out to deliver transgene into these tissues, both in vitro and in vivo. [3] [4] [5] Extensive studies have been focused over the years on the human immunodeficiency virus type 1 (HIV-1)-based vector, which currently represents the vector of choice for many basic and applied research investigations, 6 and recently it has been approved for human clinical studies. 7 Recombinant lentiviral particle production is obtained by transiently expressing the viral structural components along with the transfer vector 1 or, to a lesser degree, by the use of stable vector-producing cell lines. [8] [9] [10] [11] For clinical application, vectors produced by stable cell lines could be preferred over the transiently generated ones, as in-depth molecular characterization of the producer line ensures a continuous source of vector particles and their extensive quality control, reducing therefore batchto-batch variation and allowing higher level of safety. Indeed, several stable packaging cell lines have been generated. [9] [10] [11] However, this approach is laborious and time-consuming, and the toxicity of lentiviral (enzymes and accessory) proteins as well as the fusogenicity of the rhabdovirus vesicular stomatitis virus G protein (VSV-G), most commonly used to pseudotype HIV-1 vector particles, requires tight control of gene(s) expression, 11 complicating constitutive production of recombinant virions. The first clinical trial by means of an HIV-1-based vector has indeed been pursued by scaling up transiently produced lentiviral particles. 7 Over the past decade, refinements of each lentivector component(s) have been performed with the emphasis focused on developing vector systems not only capable of producing high-titer recombinant particles but also having improved biosafety profiles. To decrease the chance of insertional mutagenesis as well as of generating recombinant competent virus, the transfer vector and the packaging construct have been modified and lentiviral vector sequences have been deleted or replaced by heterologous ones. Examples include deletions within the long terminal repeat as well as that of accessory and regulatory genes. [12] [13] [14] [15] [16] [17] Among the latter, optimal vector production has been shown to require the Rev/Revresponsive element (RRE) interaction, as it positively affects the nuclear export of both the unspliced gag-pol and the transfer vector mRNAs. 18, 19 Heterologous viral sequences known to enhance export and/or stability of unspliced transcripts have been used to replace the RRE sequences. 20, 21 An alternative approach is represented by cytoplasmic production of retroviral particle that can be achieved by the development of hybrid vectors between retroviral vectors and a second viral vector system that does not recognize nuclear transcription and processing. 22, 23 Among the latter, the ability of the Semliki Forest virus (SFV), an alphavirus, to replicate exclusively in the cytoplasm allows to maximize the efficiency of gene expression by overcoming problems associated with splicing, limitation in transcription factors, capping process and mRNA nucleus/cytoplasm transport. 24 Moreover, the simple and rapid production of high-titer virus and its ability to be adapted to growth in suspension cell cultures in bioreactors and spinner flasks 25, 26 have made alphavirus particularly attractive for gene expression studies. The most commonly used alphaviral system is based on two plasmids: (1) an expression vector containing the non-structural viral genes (required for RNA replication) and the foreign gene(s) of interest inserted downstream the strong subgenomic promoter and (2) a two-helper system containing the viral structural genes (capsid and membrane protein genes) required for the assembly of recombinant alphaviral particles. 27, 28 Upon the infection of cells, the positive-strand viral genomic RNA is released into the cytoplasm and immediately translated to produce the viral replicase (an RNA-dependent RNA polymerase), which both (i) catalyzes the formation of new genomic RNAs through negative-stranded RNA intermediate and (ii) recognizes a subgenomic promoter contained in the negative-stranded RNA template from which the heterologous gene will be transcribed, leading to high levels of antigen production. Although alphavirus systems have been usually adopted for overexpression of a protein, 29 heterologous RNA synthesis under the alphaviral subgenomic promoter can be accomplished. Indeed, the use of SFV-derived vectors to produce recombinant gamma retroviruses has been proposed, and it has been shown that RNA-based SFV expression system can be used for the production of Moloney murine leukemia virus particles at high titers. [30] [31] [32] In this context, it has been reported that SFV replicons could be packaged within recombinant retroviral particles, including murine gamma retrovirus 33, 34 and lentivirus, 34 indicating that the production of retroviral particles under SFV-based transcriptional control must be prohibited in gene therapy approaches. In this study, to gain further insights into mobilization of SFV replicons by means of lentiviral particles, we designed a chimeric SFV/HIV vector system that contains both the HIV-1 cis-and transacting elements under the transcriptional control of the SFV replicase and investigated the ability of the hybrid SFV/HIV system to produce recombinant lentiviral particles capable of transducing target cells.
Results

Construction of SFV chimeric replicons
To obtain SFV-HIV chimeric particles, we firstly expressed the cis-and the trans-acting elements of the lentiviral system (Gag-Pol, Env and the vector unit) under the transcriptional control of the SFV replicase. To this end, third-generation HIV-1 vector sequences, 14 containing a cytomegalovirus (CMV) promoter-driven chloramphenicol acetyltransferase (CAT) reporter gene, were cloned into the pSFV4.2 vector, generating the SFV/ HIV CAT chimeric plasmid, as schematically represented in Figure 1 . Similarly, trans-acting elements, including the full-length coding region of the HIV-1 Gag-Pol precursor and the sequence of the VSV-G, currently the most widely envelope glycoprotein adopted to pseudotype lentiviral vector given its broadened host range, 35 were inserted into the pSFV4.2 vector, obtaining the pSFV/ Gag-Pol and the pSFV/VSV G plasmids, respectively ( Figure 1 ). All plasmids contain the elements required for cytoplasmic autocatalytic replication of the in vitrosynthesized RNA.
Expression of the HIV-1 cis-and trans-acting elements through the Semliki replicon system
As the replication of SFV occurs exclusively in the cytoplasm, many difficulties that may occur in nuclear gene expression, such as limitation of transcription factors and problems with RNA splicing or transport, are absent. To determine whether the SFV expression system could allow the expression of both the HIV-1 cisand trans-acting elements, we investigated the expression of the chimeric replicons by transient transfection of 293T cells. Each chimeric plasmid, pSFV/HIV CAT , pSFV/ Gag-Pol or pSFV/VSV G , was used as a template for in vitro transcription of the corresponding recombinant mRNA. The level of RNA synthesis was assessed by semiquantitative reverse transcriptase-PCR on equivalent amount of total RNA extracted from 293T-trans- Oligonucleotides complementary to either plus-or minus-strand RNA were used for the detection of strand-specific cDNA. Next, a Gag fragment in both the SFV/HIV CAT and the SFV/Gag-Pol replicons, as well as a VSV-G fragment in the SFV/VSV G chimeric construct were amplified by PCR. 36 Both plus-(genomic and subgenomic) and minus-strand RNAs were detected, at similar levels, starting from 5 h post-transfection, suggesting the efficient replication of each SFV/HIV chimeric replicon (data not shown). Then, the ability of the SFV/HIV CAT replicon to mediate gene expression was investigated by determining the CAT activity in terms of conversion of chloramphenicol into its acetylated forms. As reported in Figure 2a , CAT activity was observed starting from 10 h post-transfection and increased over time. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis was performed to analyze cell-associated and extracellular HIV-1 proteins at 24 and 48 h posttransfection with the SFV/Gag-Pol replicon. Figure 2b (left panel) shows the HIV-1 proteins detectable in the cell lysate: Pr55 Gag, the cleavage product p41 and the viral capsid p24 are clearly visible, as expected by the use of an anti-p24 serum. The presence of fully processed structural proteins strongly indicates that the SFV/GagPol RNA expressed functional viral protease. In addition, the use of a specific anti-reverse transcriptase (RT) antibody allowed the detection of RT expression ( Figure  2b , upper right panel). To determine whether the SFV replicase could allow VSV-G expression, we examined transfected cells by SDS-PAGE and western blot analysis using an anti-VSV-G serum. As shown in Figure 2b (lower right panel), VSV-G was correctly expressed at different times after transfection. Moreover, the ability of the SFV/Gag-Pol replicon to drive the release of mature virus-like particles in the culture supernatant was also shown (Figure 2c ).
Production of SFV recombinant particles
Next, we evaluated the ability of the SFV expression system to drive the formation and the release of SFV recombinant particles, capable of incorporating chimeric SFV/HIV genomic RNA. Baby hamster kidney cells (BHK-21) were co-electroporated with recombinant in vitro-transcribed SFV/HIV CAT , SFV/Gag-Pol or SFV/ VSV G replicon along with defective SFV/Helper C and SFV/Helper S RNAs. 29 Firstly, we analyzed the presence and the amount of SFV recombinant particles in the To this end, we exploited the SYBR Green real-time technology and a quantitative assay was designed to detect SFV chimeric RNA in all recombinant virions by using specific primers mapping in the SFV replicase coding sequence in order to overcome experimental differences during the amplification reaction. Moreover, an SFV replicon containing the enhanced green fluorescence protein (eGFP) gene under the control of the SFV subgenomic promoter was used as a control (SFV/eGFP). Quantification using this assay was linear over the range of standard RNA dilutions analyzed. PCR products were subjected to a melting curve analysis to exclude the amplification of unspecific products. In different repeated experiments, the amount of genomic RNA target molecules was around 10 8 RNA molecules/ml for each different replicon (that is SFV/HIV CAT , SFV/Gag-Pol, SFV/VSV G and SFV/eGFP). In parallel, to correlate the RNA amount with the infectivity of the viral particles, the titer of the SFV/eGFP virions was determined by transducing 293T cells and analyzing GFP-positive cells by flow cytometry. The observed titers in transducing units/ml (TU/ml) were roughly 1 log lower compared with the ones obtained as genomic RNA (RNAs/ml). This finding, being in agreement with earlier observations reported in the literature, [37] [38] [39] validates our real-time PCR method. The higher RNA titers are most likely due to the presence of defective interfering particles and do not appear to be due to plasmid DNA, as we conducted the PCR analysis of supernatants in the presence and absence of reverse transcription to exclude DNA background. Our results reinforce the observation that RNA titers from supernatants overestimate the actual number of functional vector particles. Nevertheless, most of the SFV recombinant RNAs detected in the cellular supernatant is likely to be associated with recombinant infectious particles capable of transducing target cells.
Transduction of target cells by SFV recombinant particles
To investigate the ability of each replicon, SFV/HIV CAT , SFV/Gag-Pol and SFV/VSV G , to be packaged into SFV- SFV/HIV hybrid vectors C Del Vecchio et al like particles that are able to transfer and efficiently express into target cells the corresponding transgene, 293T cells were infected with recombinant SFV/HIV CAT , SFV/Gag-Pol or SFV/VSV G particles at different multiplicities of infection (MOIs). An MOI of 0.1-1 was used to ensure that a large percentage of cells would be infected but likely with only a single infectious particle so that any differences measured between the replicon particle preparations would be based on a large number of events. The ability of the SFV/HIV CAT chimeric particles to mediate gene transfer was analyzed at 24 and 48 h post-transduction by measuring the CAT activity in the cell lysates (Figure 3a) . The results indicate that the SFV/ HIV CAT genome is incorporated into SFV particles, delivered and expressed into the target cells. Gag gene products were detected in the cell lysates transduced with SFV/Gag-Pol particles (Figure 3b , left panel). The presence of partially (p41, p25) and fully (p24) processed gag gene products indicates that the viral protease is active. In addition, both the HIV-1 p66 and p51 RT subunits were detectable in the infected cell lysates (Figure 3b , upper right panel). Similarly, VSV-G was detected at high levels in cells transduced with SFV/ VSV G chimeric particles at 48 h post-transduction, as shown in Figure 3b (lower right panel). Moreover, we were able to show that 293T cells transduced with SFV/ Gag-Pol efficiently release in the supernatant mature virus-like particles (Figure 3c ). Altogether, our results strongly suggest that the SFV/HIV particles can efficiently transfer and express the cis-and trans-acting elements of an HIV-1-based vector system.
SFV-mediated HIV-1 particles production and transducing ability
Next, we investigated whether the hybrid SFV/HIV system could be adopted for the production of infectious pseudotyped HIV-1 particles. For this purpose, 293T cells were co-transduced with a combination of SFV/HIV CAT , SFV/Gag-Pol and SFV/VSV G particles at 1, 0.35 and 0.35 MOIs, respectively. Firstly, we examined the expression of the lentiviral cis-and trans-acting elements in cotransduced cells. As shown in Figure 4 , CAT activity and VSV-G expression were detectable in the cell lysates (panels a and upper right b). Moreover, the Gag and the Gag-Pol precursors were present in their mature cleaved form both in cell extract and in supernatant (panels lower right b and c). Thus, this result suggests that cotransduced cells could allow successful expression of each vector component. Then, we evaluated lentiviral vector titers by real-time PCR using specific primers mapping in the CAT coding sequence within the HIV-1 vector genomic RNA. Particles released in the supernatant of co-transduced cells yielded a titer ranging from 10 3 to 10 5 RNAs/ml. When we used the recombinant lentiviral particles to infect 293T cells, the level of CAT activity detectable in target cells was 2.3±0.9. By using similar amounts of (Figure 5a ). Piver and collaborators 34 have recently shown the mobilization of full-length SFV replicons by retroviral particles. Therefore, we investigated the presence of the SFV/Gag-Pol and the SFV/VSV G replicons, as well as that of the SFV/Helper C and the SFV/Helper S replicons, in the supernatant of co-transduced cells by real-time PCR using specific primers for the Gag, the VSV-G, the SFV/Helper C and the SFV/Helper S coding sequences. The amount of these chimeric replicons ranged between 10 3 and 10 4 RNAs/ml. As support of these findings, Gag-Pol proteins and VSV-G were expressed in transduced cells (Figure 5b) .
Altogether, these results indicate that the chimeric replicons are mobilized by lentiviral particles, delivered and expressed in target cells in an SFV replicasedependent manner.
Discussion
Retroviral vectors are still the vectors that are used in the majority of gene therapy trials for the treatment of acquired or inherited diseases. Among them, lentiviral vectors have great potential given their ability to transduce non-dividing cells. Currently, lentiviral particle production is achieved by transient expression of the lentivector components or, to a lesser extent, by the use of stable packaging cells. Alternatively, the development of hybrid vectors has been investigated to combine desirable properties of the retroviral vectors with those of other vector systems. 22, 23, 40 In this context, the simple and rapid cytoplasmic production of high titer virus has made alphaviruses attractive. Indeed, the use of SFVderived vectors to produce recombinant retroviral particles has been proposed. [30] [31] [32] [33] However, despite the attractive features, this approach has shown that SFV replicons could be packaged within the recombinant particles, 34, 41 rendering it unsuitable in gene therapy application for safety reasons. The purpose of this study was to clarify this issue by adopting an SFV/HIV hybrid system for the expression of the HIV-1 vector elements under the transcriptional control of the SFV replicase and for the production of transducing pseudotyped lentiviral particles. By transfecting target cells with each of the SFV-derived HIV-1 vector elements, we show that expression of both the HIV-1 vector cis-and trans-acting components could be achieved and that recombinant SFV-like particles, able to transfer and to allow efficient expression of the SFV replicons in transduced cells, could be obtained by providing in trans the SFV structural proteins. In an attempt to produce infectious pseudotyped HIV-1 virions, target cells were co-transduced with the SFV/HIV chimeric particles. Gag-Pol and VSV-G were efficiently expressed, whereas the expression of the reporter CAT gene, contained within the HIV-1 vector unit, was lower compared with the one obtained in target cells transduced with SFV/HIV CAT particles. Moreover, the transducing ability of the pseudotyped HIV-1 particles released from co-transduced target cells was not efficient. Pseudotyped HIV-1 particle titers of 10 3 -10 5 RNAs/ml were routinely obtained, and in one single experiment, up to 10 7 RNAs/ml could be generated 
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(data not shown), indicating that the system can still be optimized. Decreased amount of viral vector RNA incorporated into pseudotyped HIV-1 particles compared with the one incorporated into SFV/HIV CAT particles could in part account for the low transducing ability observed. Indeed, in the case of SFV/HIV CAT , the presence of an SFV capsid protein would be expected to allow selectivity in viral genome packaging in SFV/ HIV CAT particles, even though several evidence has suggested that, besides the specific interaction of the alphavirus capsid with packaging signals, some other mechanism(s) might be involved in RNA packaging. 42, 43 One important consideration might be the effect of the SFV/HIV CAT vector expression level in the co-transduced cells. However, even though the expression of the SFV/HIV CAT vector in transfected cells was not particularly high, efficient transducing ability of SFV/HIV CAT particles was achieved. Piver et al. 34 have recently shown that SFV vectors are efficiently incorporated into gamma retroviral and lentiviral particles in a retroviral packaging sequenceindependent manner. Our results are in agreement with these findings, as when we analyzed the pseudotyped HIV-1 particles released from co-transduced target cells, SFV/Gag-Pol, SFV/VSV G , as well as SFV/Helper C and SFV/Helper S replicons could be detected. Similarly, Gag-Pol proteins and VSV-G were found to be expressed in target cells transduced with pseudotyped HIV-1 particles, although at low level. It has been reported that the RNA has a crucial role in the structural integrity of the retroviral particle and that selective and non-selective packaging of cellular RNAs can occur both in murine leukemia virus and in HIV-1 particles. 41, 44, 45 Moreover, it has been shown that HIV-1-based vectors with deletions of SL1-SL4, the region encompassing sequences involved in targeting viral RNA into virions as high-affinity binding site for Gag, 46, 47 can still be packaged and transduced, although with no apparent normal dimerization, suggesting the presence of a c-independent mechanism of packaging. 48 Thus, alternative and not mutually exclusive explanations have to be taken into account to explain the lack of high efficiency of pseudotyped HIV-1 particles transducing ability.
The major difference between the study by Piver and co-workers 34 and our current study is that they adopted an SFV-based vector containing a non-functional internal 26S promoter, which should lead to the exclusive production of full-length SFV genomic RNA 49 and a reporter gene under the transcriptional control of the SFV replicase. In contrast, our system is characterized by the SFV replicase, which regulates transcription of the entire cis-acting element of the lentiviral component, that is the HIV-1 vector unit, and by the presence of a wildtype 26S subgenomic promoter. Retroviral packaging of subgenomic SFV genome has been shown to occur, 41 and it is possible to mobilize SFV replicons by making VLPs, which are able to package genomic as well as subgenomic RNAs. 50, 51 Thus, recombinant HIV-1 virions produced by cells co-transduced with SFV/HIV particles may incorporate different genomic and subgenomic RNAs ( Figure 6 ). Our data seem to indicate that, among them, both the genomic and subgenomic RNAs containing the HIV-1 vector unit are negatively selected, despite the fact that SFV-driven HIV-1 vector genome is the only one containing a lentiviral packaging sequence.
A possible explanation for this finding could be the highly structured HIV-1 long terminal repeat along with its flanking sequences containing the packaging signal that would affect, on one hand, the accessibility of viral/ cellular proteins to the packaging signal and, on the other hand, the overall conformational folding of secondary structure of the vector genomic RNA, 52 with a negative impact on transcription efficiency by the subgenomic promoter. In addition, we cannot completely exclude that our vector design, although based on the results of our group and others, might also contribute to the observed low level of lentiviral particle transducing ability. Indeed, cis-acting elements present or absent in the SFV/HIV CAT may have, respectively, a negative or positive effect on reverse transcription, packaging and gene expression. More studies are required to address these specific issues.
During the SFV life cycle, after a receptor-mediated endosome-dependent entry step, the cytoplasmic SFV replicons are associated with membrane structure, plasma membrane as well as endosomal and cytoplasmic vacuole derivatives, 53 the latter been suggested to be the sites of virus-specific RNA replication. These steps are likely to take place in target cells transduced with each SFV/HIV CAT , SFV/Gag-Pol and SFV/VSV G particles, as high efficiency of transgene expression as well as particle release could be achieved. By contrast, a different situation might be occurring in co-transduced target cells, where impaired coordination of replication, translation and assembly of lentiviral components necessary to achieve accurate formation of transducing lentiviral particle could take place. Expression of SFV-driven lentiviral vector elements may influence intracellular RNA transport of the SFV replicon, ultimately affecting its cytosolic fate. Indeed, it has been recently reported that the Rev/RRE interaction, in addition to the shuttling of viral RNAs containing the RRE by a cellular export pathway from the nucleus to the cytoplasm, contributes to enhanced encapsidation of genomic lentiviral RNA. 54 As Rev is not included in the viral particle, it is likely that Rev may act indirectly, possibly by targeting the viral RNA to a cytoplasmic compartment favorable for RNA encapsidation. 54 Poole and co-workers 55 recently showed that, in HIV-1, for efficient packaging to occur, RNA and Gag had to interact at a certain point within the cell. Moreover, it has been reported that Mason Pfizer Monkey virus (M-PMV) assembles in a pericentriolar compartment and that trafficking to this compartment is necessary for correct capsid assembly and the production of infectious virus. 56 Finally, the activity of the HIV-1 RNA export elements has also been proposed to influence virus assembly. 57 Thus, it could be possible that, within the hybrid SFV/HIV system, the establishment of cytosolic compartments or microdomains is required to allow colocalization of both the vector RNA and the viral proteins and to facilitate their access to cellular factors involved in recombinant particle formation/release. 58, 59 The design of the genetic elements and the optimal ratio of viral proteins and genomic RNA, as well as their colocalization, are important factors in attempt to achieve high-level production of lentiviral vector particles. In this study, we provide interesting data relevant to the design of chimeric lentiviral vectors. Understanding of the packaging specificities and detailed studies on penicillin and 100 mg ml À1 streptomycin (Sigma, St Louis, MO, USA). BHK-21 and 293T cells have been reported to be the best target for SFV replication. 60 
Materials and methods
Genetic constructs
The pSFV4.2 plasmid and the SFV split-helper system were kindly provided by P Liljeströ m (Karolinska Institutet, Stockholm, Sweden). Briefly, the pSFV4.2 vector contains the SFV open reading frame encoding the four non-structural proteins (nsP), designated nsP1-nsP4, responsible for the transcription and replication of the genomic viral RNA. In addition, the vector contains the 26S subgenomic promoter, which drives transgene expression, as well as the polyadenylation signal for the termination of transcription. The SFV split-helper system includes the pSFV/Helper C and the pSFV/Helper S, encoding the viral capsid (protein) and the p62/E1 envelope proteins, respectively.
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A DNA fragment of 3872 bp containing the HIV-1 vector sequences was generated by PCR amplification using the CMV.ppt.GFP plasmid 14 (kindly provided by L Naldini, San Raffaele Scientific Institute, Milan, Italy), after substitution of the reporter gene with the CAT gene, and cloned into the pSFV4.2 construct to obtain the pSFV/HIV CAT plasmid. The forward SOEA primer 5 0 -GGCGGACCGGGTCTCTCTGGTTAGACCAGATCTG AGCC-3 0 contained a RsrII restriction site at the 5 0 -end (underlined). The reverse SOEC primer 5 0 -GCGTTGCG GCCGCAAGCACTCAAGGCAAGCTTTATTGAGGC-3 0 contained as NotI restriction site at the 3 0 -end (underlined). The PCR resulted in a fragment encompassing the recombinant HIV-1 vector (R-U5-c + -CMVCAT-DU3-R) that was then inserted into the pSFV4.2 plasmid digested with RsrII and NotI. The design of the SFV/HIV CAT hybrid vector is similar to the one earlier developed for an SFV/MLV hybrid construct. 30 The recombinant retroviral genome in pSFV/HIV CAT is flanked at the 5 0 -and 3 0 -ends by 38 SFV-specific bases. Although the 5 0 ones are part of the internal SFV promoter, the 3 0 -end 38 nucleotides were inserted by fusion PCR using Vent DNA polymerase (New England Biolabs, Hertfordshire, UK) and appropriate primers. Indeed, according to the model for retroviral DNA synthesis by reverse transcription, a strong-stop DNA is synthesized near the 5 0 -end of the retrovirus RNA genome. 30 This strong-stop DNA then jumps to the 3 0 -end, and the exposed R sequence hybridizes with the complementary R sequence at the 3 0 -end of the retroviral genome for synthesizing the minus-strand DNA. The 38 SFV-specific bases present in front of the 5 0 -end R region may interfere with the minusstrand DNA synthesis. Thus, we inserted the same 38 SFV-specific bases between the 3 0 DU3 and the R regions to facilitate the conversion of the RNA into doublestranded DNA. Indeed, it has been shown that this modification allows to achieve higher vector titers in the context of SFV/oncoretroviral chimeric construct. 31 The pMDLgRRE no. 54 vector, 14 kindly provided by L Naldini (San Raffaele Scientific Institute, Milan, Italy), was used to construct the SFV/Gag-Pol vector. The HIV-1 full-length Gag-Pol coding sequences (nt 1324-5680) were obtained by digestion with PmlI and NotI and inserted into the pSFV4.2 plasmid, which had been digested earlier with BamHI, blunt ended and then digested with NotI.
The VSV-G coding sequence was obtained from the pVSV-G plasmid (kindly provided by T Friedman, University of California, San Diego, CA, USA) by BamHI digestion and inserted into the BamHI site of the pSFV4.2 plasmid to generate the pSFV/VSV G vector.
The eGFP encoding sequence was obtained from the pEGFP1 plasmid (Clontech, Saint-Germain-en-Laye, France) by BamHI and NotI digestions and inserted into the pSFV4.2 plasmid digested with the same enzyme(s) to yield the pSFV/eGFP construct.
All the plasmid-cloned fragments were verified by sequencing.
In vitro transcription and transfection
Transcripts were produced in vitro from NruI-linearized pSFV/HIV CAT , pSFV/Gag-Pol, pSFV/VSV G and SpeIlinearized pSFV/Helper C and pSFV/Helper S plasmid DNAs. Briefly, RNA was synthesized at 37 1C for 1 h in 50 ml reactions containing 2.5 mg of linearized DNAs, 40 mM Tris-HCl (pH 7.5), 6 mM MgCl 2 , 2 mM spermidine, 5 mM dithiotreitol, 1 mM of each ATP, CTP and UTP, 0.5 mM GTP, 50 U of RNasin and 100 U of SP6 polymerase. For the production of capped transcripts, the analog m 7 G(5 0 )ppp(5 0 )G was included in the reaction mixture at 1 mM concentration. 29, 61 All the reagents were supplied from Promega (Madison, WI, USA). For the transfection experiments, the transcription mixtures were purified by gel filtration using the Quick Spin Columns kit for RNA purification (Roche Diagnostics, Indianapolis, IN, USA). 293T cells were transfected with in vitro-transcribed replicon RNAs or with the pVSV-G and pMDLgRRE no. 54 plasmid DNAs, using the Lipofectamine 2000 reagent (Invitrogen), following the manufacturer's instructions.
Production of SFV replicon particles
To package recombinant RNAs into SFV particles, BHK-21 cells were electroporated with purified transcription mixtures including each replicon (SFV/HIV CAT , SFV/ Gag-Pol or SFV/VSV G ) along with the two helper RNAs, as described earlier. 29 The cells were trypsinized, washed three times with ice-cold phosphate-buffered saline (PBS) and finally resuspended in PBS at a density of 10 7 cells/ 500 ml, before being transferred to a 0.2-cm electroporation cuvette (Eppendorf, Hamburg, Germany) and incubated with 50 ml of each RNA mixture. Electroporation was performed at room temperature by two consecutive pulses at 1.5 kV and 25 mF, using a Bio-Rad Gene Pulser apparatus with the pulse controller unit set at maximum resistance (Bio-Rad, Hercules, CA, USA).
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The cells were diluted at least 1:20 in complete DMEM medium and transferred onto tissue culture plates. After 24 h of electroporation, cell culture supernatants were harvested, filtered through 0.45 mm filters (Millipore, Molsheim, France), aliquoted and stored at À80 1C.
Titration of recombinant SFV particles by real time PCR
Viral RNA was extracted from a 200 ml aliquot of recombinant viral suspension using the Viral RNA extraction kit (Qiagen, Valencia, CA, USA). To remove contaminating DNA, that is plasmid DNA carried over from the production of vector, 38 viral RNA was treated with 30 U of RNase-free DNase I (Roche Diagnostics) at 37 1C for 30 min and heat-inactivated at 95 1C for 15 min, followed by quick cooling on ice. cDNA was prepared from 2 mg of total RNA in a 50 ml reaction mixture containing 1 mM Tris-HCl (pH 8.3), 5 mM KCl, 5.5 mM MgCl 2 , 2.5 mM random hexanucleotide primers, 0.5 mM of each dNTP, 40 U of RNase inhibitor and 125 U of MLV RT (Applied Biosystems, Foster City, CA, USA). RNA samples were incubated in the reaction mixture at 25 1C for 10 min, at 42 1C for 50 min and then at 95 1C for 5 min. To determine the background due to the presence of any residual DNA left after DNase treatment, the PCR was also conducted in the absence of RT. The real-time PCR was carried out in a final volume of 50 ml using the reaction buffer containing double-stranded DNA-specific SYBR Green I dye for the detection of PCR products (2 mM MgCl 2 , 0.2 mM of each dATP, dCTP and dGTP, 0.4 mM of dUTP, 0.25 mM of each specific primer, 1.25 U of AmpliTaq Gold DNA polymerase and 5 ml of cDNA sample). Each real-time PCR run included the setting up of a 6-point standard curve using 5 ml of serial 10-fold template DNA (that is, pSFV/HIV CAT , pSFV/Gag-Pol, pSFV/VSV G , as well as pSFV/Helper C and pSFV/ Helper S) dilutions, ranging from 10 to 10 6 copies, as measured by the spectrophotometric analysis, in nuclease-free water. 62 After an initial denaturation step at 95 1C for 10 min, amplification was performed at 95 1C 0 . The primers were designed to amplify sequences encompassing the SFV replicase, capsid and envelope, as well as the 5 0 -end of Gag, the VSV-G and the CAT encoding regions.
Transduction with recombinant SFV particles
293T cells were seeded onto six-well tissue culture plates dishes at a density of 2 Â 10 5 washed twice with PBS and transduced with recombinant alphaviral particles using a range of different MOIs in the presence of minimal essential medium (Sigma). After a 5 h adsorption, recombinant particles were removed and complete DMEM medium was added.
Western blotting analysis
At 24 or 48 h post-transfection or post-transduction, 293T cells were collected and lysed in radioimmunoprecipitation assay buffer (140 mM NaCl, 8 mM Na 2 HPO 4 , 2 mM NaH 2 PO 4 , 1% (v/v) Nonidet P-40, 0.5% (v/v) sodium deoxycholate, 0.05% (v/v) SDS). Aliquots of the cell lysates were resolved by SDS-PAGE and electroblotted onto Hybond-C Extra membranes (GE Healthcare, Chalfont St Giles, UK). The membranes were incubated with a rabbit anti-p24 polyclonal antiserum (Advanced Biotechnologies, Rivers Park II, Columbia, MA, USA), a monoclonal anti-RT (p66/51) antiserum (Advanced Biotechnologies) or a mouse anti-VSV-G monoclonal antiserum (Sigma), followed by a peroxidase-conjugated anti-rabbit or anti-mouse Ig antibody (GE Healthcare). Blots were developed by using enhanced chemiluminescence reagents (GE Healthcare), as described earlier. 63 
HIV-1-like particles analysis
293T cells were analyzed at 24 and 48 h post-transfection or post-transduction. The culture supernatants were collected, clarified by low-speed centrifugation and filtration through 0.45 mm filters (Millipore). HIV-1-like particles released were spun through 20% sucrose cushions (in PBS) at 27 000 r.p.m. in a Beckman SW41 rotor (Beckman Instruments, Palo Alto, CA, USA) for 2 h at 4 1C and lysed in radioimmunoprecipitation assay buffer. Virus pellets were analyzed by SDS-PAGE followed by western blotting with either an anti-p24 polyclonal antiserum or a monoclonal anti-RT (p66/51) antiserum (Advanced Biotechnologies).
CAT assay
To assess the transduction ability of the lentiviral particles, transduced cells were collected at different time points and lysed. Equivalent amounts of protein (from 40 to 70 mg), assessed with the Micro BCA Protein Assay Kit using the BSA as a standard (Pierce Biotechnology, Rockford, IL, USA), were adopted to determine CAT activity, as described earlier. 64 Only values within the linear range were considered in order to calculate the relative CAT activities.
